RNA-based technology, including mRNA vaccines and other therapeutics, have had a tremendous impact on human health recently, especially through the advent of mRNA-based COVID vaccines. Ontario has considerable expertise in this field, and we are making a big push to be a global leader in developing novel RNA-based medicines that will benefit our healthcare system and help millions of people around the globe. At this forum, we will address questions around the status of technology behind RNA therapeutics, critical gaps in knowledge and barriers to clinical adoption of RNA nanomedicine. These questions will revolve around selective targeting, personalization of therapy and strategies for moving these therapies safely to the clinic.